How many units of Adipotide (FTPP) should I draw?

It depends on your vial size, BAC water, and dose. For a 5mg vial with 2mL BAC water, a beginner dose of 0.5mg is typically 0 units on a U-100 syringe. Use the calculator above for your exact numbers.

How much BAC water should I add to Adipotide (FTPP)?

The standard amount is 2mL of bacteriostatic water for a 5mg vial. More water gives a more dilute solution — easier to measure small doses. Less water means fewer injections per vial. Adjust the BAC water slider in the calculator to see how it changes your syringe units.

How long does a Adipotide (FTPP) vial last?

At a beginner dose of 0.5mg daily, a 5mg vial lasts about 10000 doses. The calculator shows exact doses per vial for your selected tier.

What syringe should I use for Adipotide (FTPP)?

Most people use a U-100 insulin syringe (1mL / 100 units). For very small doses, a U-50 or U-30 syringe gives better precision. The calculator adjusts units automatically for whichever syringe you pick.

Adipotide (FTPP) Dosage Calculator

Weight LossInjectionResearch~2-4 hours half-life

Adipotide, also known as FTPP (Fat-Targeted Proapoptotic Peptide) or Prohibitin-TP01, is a synthetic peptidomimetic designed to selectively destroy the blood vessels that supply white adipose tissue.

7-15% body weight reduction in 28 days observed in obese primates38% total body fat reduction and 27% abdominal fat reduction in primate studiesTargets white adipose tissue vasculature with high selectivity via prohibitin bindingImproved insulin resistance observed alongside fat loss in primate models4 weeks on / 8 weeks off

Vial Size

BAC Water (mL)

Dosing Level

0.5mcg · Daily

Custom Dose (mcg) — optional

Syringe Type

0.0 units

100 units (1mL)

Concentration

2,500

mcg/mL

Draw Volume

< 0.001

Syringe Units

< 0.1

units

Doses / Vial

10000

doses

Very small draw (< 0.1 units) — difficult to measure accurately. Consider using less BAC water for a more concentrated solution.

Try 0.5mL BAC water for an easier-to-measure draw.

Summary: Add 2mL BAC water to your 5mg vial. Draw to < 0.1 units on a U-100 syringe for a 0.5mcg dose. This vial will last 10000 doses.

Cycle Planner

Cycle Length (weeks)

Price Per Vial ($) — optional

Subcutaneous. Typical beginner frequency: daily.

Adipotide (FTPP) Pharmacokinetics

Pharmacokinetics — Active Dose Over Time

t½ = ~2-4 hours (estimated)

After 1 half-life (3h): 50% remainsAfter 2 half-lives (6h): 25% remainsAfter 3 half-lives (9h): 12.5% remains

At a 1mcg dose: 50% = 1mcg remaining after 3h. Recommended frequency: Daily.

Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.

Adipotide (FTPP) Dosing Protocol

Level	Dose / Injection	Frequency
Beginner	0.5mg	Daily
Moderate	1mg	Daily
Aggressive	2mg	Daily

Note: WARNING: Clinical development permanently discontinued due to nephrotoxicity. Phase 1 human trial terminated early. Subcutaneous injection. Primate studies used 28-day treatment cycles at 0.43 mg/kg daily. This compound carries a high safety burden and should only be considered in a supervised research context with renal monitoring. The therapeutic window between fat-reducing and kidney-damaging doses is extremely narrow.

About Adipotide (FTPP)

Adipotide, also known as FTPP (Fat-Targeted Proapoptotic Peptide) or Prohibitin-TP01, is a synthetic peptidomimetic designed to selectively destroy the blood vessels that supply white adipose tissue. It consists of two functional domains: a cyclic homing peptide (CKGGRAKDC) that binds to prohibitin on the surface of adipose tissue endothelial cells, and a proapoptotic sequence D(KLAKLAK)2 that disrupts mitochondrial membranes once internalized, triggering programmed cell death in those endothelial cells. When the vasculature feeding fat depots is destroyed, the downstream adipocytes are starved of oxygen and nutrients, leading to fat cell death and tissue resorption. In preclinical mouse studies published in Nature Medicine in 2004, adipotide reversed diet-induced obesity by approximately 30% over four weeks. In a 2011 primate study published in Science Translational Medicine, obese rhesus monkeys treated with adipotide for 28 days lost 7-15% of body weight, with a 38% reduction in total body fat and a 27% reduction in abdominal fat as confirmed by MRI and DEXA. Insulin resistance also improved significantly. However, the same primate studies revealed dose-dependent renal injury, with kidney lesions ranging from minimal to moderate depending on dose level. Arrowhead Research initiated a Phase 1 human trial in 2012, but it was terminated due to unacceptable nephrotoxicity. The therapeutic window between effective fat-reducing doses and kidney-damaging doses proved too narrow for safe clinical use, and all clinical development was permanently discontinued in 2019. Adipotide remains one of the most striking examples of a research compound that achieved dramatic efficacy but could not overcome its own toxicity profile. It is not approved by any regulatory agency and is available only as a research chemical.

View full Adipotide (FTPP)guide →Add to schedule →